The efficacy and safety of tesofensine for weight loss in obese subjects. A 24-week randomised, double-blind, placebo-controlled Danish multi-centre trial

被引：0
|
作者：
Astrup, A. [1 ]
Madsbad, S. [2 ]
Breum, L. [3 ]
Kroustrup, J. P. [4 ]
Jensen, T. J. [5 ]
Larsen, T. M. [1 ]
机构：
[1] Univ Copenhagen, Fac Life Sci, Dept Human Nutr, DK-1168 Copenhagen, Denmark
[2] Hvidovre Univ Hosp, Dept Endocrinol, Hvidovre, Denmark
[3] Koge Hosp, Dept Med, Aalborg, Denmark
[4] Aalborg Hosp, Dept Endocrinol, Aalborg, Denmark
[5] Cyncron Clin Res Unit, Copenhagen, Denmark
来源：
INTERNATIONAL JOURNAL OF OBESITY | 2008年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [1] The effect of tesofensine on weight loss, appetite, physical activity and QOL in obese subjects. Results from a 24-week randomised, double-blind placebo-controlled trial
    Astrup, Arne
    Madsbad, Sten
    Breum, Leif
    Kroustrup, Jens P.
    Jensen, Thomas J.
    Larsen, Thomas M.
    [J]. DIABETES, 2008, 57 : A739 - A739
  • [2] Efficacy and safety of Obex® in overweight and obese subjects: a randomised, double-blind, placebo-controlled clinical trial
    Cabrera-Rode, Eduardo
    Cubas-Duenas, Ileana
    Rodriguez Acosta, Janet
    Cruz Hernandez, Jeddu
    Conesa Gonzalez, Ana Ibis
    Gonzalez Calero, Teresa M.
    Arnold Dominguez, Yuri
    Hernandez Rodriguez, Jose
    Reyes Rodriguez, Antonio D.
    Alvarez Alvarez, Aimee
    Echevarria Valdes, Ragmila
    Jorge Espinosa, Liudmila
    Torres Belent, Onelia
    Bell Benavides, Zoila
    Senra Estevez, Elizabeth
    Abreu Rodriguez, Yanet
    del Valle Rodriguez, Juana
    Marin Julia, Silvia
    [J]. BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2023, 23 (01)
  • [3] Efficacy and safety of Obex® in overweight and obese subjects: a randomised, double-blind, placebo-controlled clinical trial
    Eduardo Cabrera-Rode
    Ileana Cubas-Dueñas
    Janet Rodríguez Acosta
    Jeddú Cruz Hernández
    Ana Ibis Conesa González
    Teresa M. González Calero
    Yuri Arnold Domínguez
    José Hernández Rodríguez
    Antonio D. Reyes Rodríguez
    Aimee Álvarez Álvarez
    Ragmila Echevarría Valdés
    Liudmila Jorge Espinosa
    Onelia Torres Belent
    Zoila Bell Benavides
    Elizabeth Senra Estévez
    Yanet Abreu Rodríguez
    Juana del Valle Rodríguez
    Silvia Marín Juliá
    [J]. BMC Complementary Medicine and Therapies, 23
  • [4] Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial
    Boffito, Marta
    Fox, Julie
    Bowman, Christine
    Fisher, Martin
    Orkin, Chloe
    Wilkins, Edmund
    Jackson, Akil
    Pleguezuelos, Olga
    Robinson, Stuart
    Stoloff, Gregory A.
    Caparros-Wanderley, Wilson
    [J]. VACCINE, 2013, 31 (48) : 5680 - 5686
  • [5] A randomised, double-blind, placebo-controlled 24-week trial of aripiprazole in recently remitted bipolar I patients
    Bahk, W. M.
    Woo, Y. S.
    Chung, M. Y.
    Kim, D. H.
    Yoon, B. H.
    Lee, J. H.
    Ahn, Y. M.
    Kim, J. K.
    Lee, K. H.
    Min, K. J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S482 - S482
  • [6] Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
    Astrup, Arne
    Madsbad, Sten
    Breum, Leif
    Jensen, Thomas J.
    Kroustrup, Jens Peter
    Larsen, Thomas Meinert
    [J]. LANCET, 2008, 372 (9653): : 1906 - 1913
  • [7] Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents:: a placebo-controlled, double-blind, randomised trial
    Sramek, JJ
    Leibowitz, MT
    Weinstein, SP
    Rowe, ED
    Mendel, CM
    Levy, B
    McMahon, FG
    Mullican, WS
    Toth, PD
    Cutler, NR
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (01) : 13 - 19
  • [8] Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial
    J J Sramek
    M T Leibowitz
    S P Weinstein
    E D Rowe
    C M Mendel
    B Levy
    F G McMahon
    W S Mullican
    P D Toth
    N R Cutler
    [J]. Journal of Human Hypertension, 2002, 16 : 13 - 19
  • [9] A randomised, double-blind, placebo-controlled, multi-centre trial to evaluate the safety and efficacy of eculizumab in patients with relapsing neuromyelitis optica: the PREVENT study
    Wingerchuk, D. M.
    Palace, J.
    Cavus, I.
    O'Brien, F.
    Pittock, S. J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 759 - 759
  • [10] A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
    Rogers, SL
    Farlow, MR
    Doody, RS
    Mohs, R
    Friedhoff, LT
    Albala, B
    Baumel, B
    Booker, G
    Dexter, J
    Farmer, M
    Feighner, JP
    Ferris, S
    Gordon, B
    Gorman, DG
    Hanna, G
    Harrell, LE
    Hubbard, R
    Kennedy, J
    McCarthy, J
    Scharre, DW
    Schaerf, F
    Schneider, L
    Seltzer, B
    Siegal, A
    Stark, SR
    Strauss, A
    Walshe, TM
    [J]. NEUROLOGY, 1998, 50 (01) : 136 - 145
12345